Coronavirus Disease 2019 (COVID-19)

This update is current as of 3:00 p.m. on the date it was posted.

This document is a collation of resources for your reference. For official guidance on COVID-19 in Ontario, please visit the Ministry of Health.

Table of Contents

New Content (updated daily).................................................................................................................................................. 3
Public Health Agencies......................................................................................................................................................... 3
   Public Health Agency of Canada | canada.ca ..................................................................................................................... 3
   BC Centre for Disease Control | bccdc.ca ......................................................................................................................... 4
   Institut national de santé publique | inspq.qc.ca ............................................................................................................. 4
   International (outside of Canada)........................................................................................................................................ 5
   CDC: Centers for Disease Control and Prevention | cdc.gov ......................................................................................... 5
   ECDC: European Centre for Disease Prevention and Control | ecdc.europa.eu ................................................................. 6
   FDA: U.S. Food & Drug Administration | fda.gov ...................................................................................................... 6
   Public Health England | gov.uk.................................................................................................................................................. 7
   World Health Organization | who.int ........................................................................................................................................ 7
   Other relevant government bodies / health care organizations ......................................................................................... 8
Research Institutes................................................................................................................................................................. 9
   Centre for Global Infectious Disease Analysis | imperial.ac.uk/mrc-global-infectious-disease-analysis/ .................................................. 9
   CIDRAP: Center for Infectious Disease Research Policy | cidrap.umn.edu .................................................................... 9
   National Collaborating Centre for Environmental Health | ncceh.ca ............................................................................. 9
   ProMED | promedmail.org .................................................................................................................................................... 9
   Updated Daily...................................................................................................................................................................... 10
   COVID-19 resources (case counts) | arcgis.com ............................................................................................................... 10
### COVID-19 Canada Open Data Working Group | COVID-19 CODWG .................................................. 10
Johns Hopkins CCSE | systems.jhu.edu ........................................................................................................... 10
NextStrain | nextstrain.org ......................................................................................................................... 10
Guidelines and Technical documents (updated weekly) ................................................................. 10

**Section I: General Guidelines** ........................................................................................................ 10
- Ontario / Canada Main Page .............................................................................................................. 10
- Case Definitions/Background Information ........................................................................................ 10
- Laboratories ....................................................................................................................................... 11
- Public Health ..................................................................................................................................... 13
- General Guidelines ............................................................................................................................ 13
- Data & Surveillance ............................................................................................................................ 14
- Testing ............................................................................................................................................... 15
- Symptoms/Treatment .......................................................................................................................... 17
- Case Investigation & Contact Tracing ................................................................................................ 18
- Infection Prevention and Control ....................................................................................................... 20
- Reopening Guidelines ........................................................................................................................ 22
- Vaccinations ....................................................................................................................................... 23

**Section III: Guidelines for the Community** .................................................................................... 26
- Community .......................................................................................................................................... 26
- Masks (Non-Medical) .......................................................................................................................... 27
- Businesses/Workplaces ........................................................................................................................ 27
- Schools / Childcare ............................................................................................................................... 28
- Mental Health / Addictions ................................................................................................................... 29
- Travel, Transport & Borders ............................................................................................................... 30
New Content (updated daily)

Public Health Agencies

Public Health Agency of Canada | canada.ca

- 2019 novel coronavirus: outbreak update
  - April 14, 2021, 19:00 EST, 1,087,152 cases of COVID-19 have been confirmed in Canada and there are currently 80,201 active cases. 23,445 people have died of COVID-19. Individuals tested: 29,363,293.
  - April 13, 2021, 19:00 EST, 1,078,562 cases of COVID-19 have been confirmed in Canada and there are currently 78,293 active cases. 23,392 people have died of COVID-19. Individuals tested: 29,251,338.
  - April 12, 2021, 19:00 EST, 1,071,016 cases of COVID-19 have been confirmed in Canada and there are currently 75,135 active cases. 23,356 people have died of COVID-19. Individuals tested: 29,142,269.

- COVID-19 vaccination in Canada
  - As of April 15, 2021, 11:00 EST, there have been 9,081,672 vaccine doses administered.
  - As of April 14, 2021, 11:00 EST, there have been 8,790,334 vaccine doses administered.

- Statement from the Chief Public Health Officer of Canada [04-15-2021]
  - “As the world continues to focus on the COVID-19 response, we must not lose sight of other important health and wellness concerns, including the impact of diabetes on Canadians. In fact, those who experience social and economic inequities face a higher risk of developing diabetes and other chronic diseases, which puts them at greater risk of severe illness from COVID-19. This is why equity matters and we must do more to support communities disproportionately affected by chronic diseases and COVID-19. At the same time, it is also more important than ever to reduce your risk of diabetes by being physically active, eating well, and not smoking. With Spring upon us, take this opportunity to get outside and be active, while still following local public health advice and maintaining individual public health practices!”

- Statement from the Chief Public Health Officer of Canada [04-14-2021]
  - “The Public Health Agency of Canada (PHAC) has received a report of a case of an individual in Canada who has experienced a very rare but serious medical event involving blood clots (thrombosis) with low levels of blood platelets (thrombocytopenia), following immunization with COVISHIELD (the Serum Institute of India version of the AstraZeneca COVID-19 vaccine). This is the first reported case of this rare adverse event in Canada. Global evidence indicates that reports of blood clots with low platelets in people following immunization with the AstraZeneca COVID-19 vaccine are very rare. Since these rare adverse events were first signalled as a possible safety issue in March 2021 in Europe, Health Canada has been working with international regulators and AstraZeneca manufacturers to review emerging data and evidence. As a
precautionary measure, while Health Canada and international regulators were assessing information relating to these reports in Europe, the National Advisory Committee on Immunization (NACI) and the Chief Medical Officers of Health recommended a pause in the use of AstraZeneca COVID-19 vaccine in all individuals less than 55 years of age in Canada. Today, Health Canada updated the AstraZeneca and COVISHIELD COVID-19 vaccine labelling information and requested the manufacturers update risk management plans for the AstraZeneca vaccine. Based on all evidence available worldwide to-date, Health Canada considers that the benefits of the AstraZeneca and COVISHIELD vaccines, in protecting against the severe outcomes of COVID-19, continue to outweigh the potential risks. As information emerges from Health Canada's ongoing assessment, including information on the adverse event reported in Canada, NACI will consider these findings and assess its recommendation in the broader public health context.”

- National Advisory Committee on Immunization (NACI) Extended dose intervals for COVID-19 vaccines to optimize early vaccine rollout and population protection in Canada in the context of limited vaccine supply [04-07-2021]
- Summary of NACI extended dose intervals statement of April 7, 2021 [04-07-2021]
- Statement from the Council of Chief Medical Officers of Health Implementing COVID-19 Vaccination in Canada [04-07-2021]
- COVID-19 information: 1-833-784-4397

BC Centre for Disease Control | bccdc.ca
- BC COVID-19 Therapeutic Committee recommendation: therapies for COVID-19 [updated 04-14-2021]
- BC COVID-19 Therapeutic Committee report on therapies for COVID-19: situation, background, assessment, recommendations [updated 04-14-2021]
- Antimicrobial and immunomodulatory therapy in adult patients with COVID-19 [updated 04-14-2021]
- Clinical guidance on COVID-19 vaccines for people with kidney disease [updated 04-08-2021]

Institut national de santé publique | inspq.qc.ca
- Données de vaccination contre la COVID-19 au Québec [04-15-2021]
- Soins personnels d’esthétique - mesures de prévention de la COVID-19 en milieu de travail [04-15-2021]
- Services policiers et agences de sécurité - mesures de prévention de la COVID-19 en milieu de travail [04-15-2021]
- Services policiers et agences de sécurité - mesures de prévention de la COVID-19 en milieu de travail [04-15-2021]
- Pompiers permanents, volontaires et forestiers - mesures de prévention de la COVID-19 en milieu de travail [04-15-2021]
- Travaux de voiries, entretien routier, travaux publics, entretien et réparation des secteurs municipal et de la construction - mesures de prévention de la COVID-19 en milieu de travail [04-15-2021]
- **Secteur de la construction - mesures de prévention de la COVID-19 en milieu de travail** [04-15-2021]
- **Options de gestion des cas de variants du SRAS-CoV-2 sous surveillance rehaussée et de leurs contacts dans la communauté** [04-13-2021]
- **Vigie de la COVID-19 dans les services de garde éducatifs à l’enfance - Avril 2021** [04-13-2021]
- **CONNECT : étude des contacts sociaux des Québécois - 13 avril 2021** [04-13-2021]
- **COVID-19 : Soins thérapeutiques en cabinet privé** [04-12-2021]
- **Services policiers et agences de sécurité - mesures de prévention de la COVID-19 en milieu de travail** [04-12-2021]

**International (outside of Canada)**

**CDC: Centers for Disease Control and Prevention | cdc.gov**

- **Update: coronavirus disease 2019 (COVID-19) in the U.S.**
  - Total cases: 31,231,869 total deaths: 561,356 [04-15-2021]
  - Total cases: 31,158,087 total deaths: 560,576 [04-14-2021]
  - Total cases: 31,076,891 total deaths: 559,741 [04-13-2021]
- **COVID-19 vaccinations in the United States**
  - Number of people receiving one or more doses: 125,822,868 [04-15-2021]
  - Number of people receiving one or more doses: 123,917,385 [04-14-2021]
- **COVID-19 stats: COVID-19 and influenza discharge diagnoses as a percentage of emergency department (ED) visits, by year - United States, June 2018-March 2021** [04-15-2021]
- **Notes from the field: update on excess deaths associated with the COVID-19 pandemic - United States, January 26, 2020-February 27, 2021** [04-15-2021]
- **Emergency department visits for COVID-19 by race and ethnicity - 13 states, October-December 2020** [04-15-2021]
- **Trends in racial and ethnic disparities in COVID-19 hospitalizations, by region - United States, March-December 2020** [04-15-2021]
- **Factors associated with participation in elementary school-based SARS-CoV-2 testing - Salt Lake County, Utah, December 2020-January 2021** [04-15-2021]
- **Safety precautions when using electrostatic sprayers, foggers, misters, or vaporizers for surface disinfection during the COVID-19 pandemic** [04-14-2021]
- **Recommendation to pause use of Johnson & Johnson’s Janssen COVID-19 vaccine**
- **Health equity in action** [04-14-2021]
- **EARLY RELEASE: Laboratory modeling of SARS-CoV-2 exposure reduction through physically distanced seating in aircraft cabins using bacteriophage aerosol - November 2020** [04-14-2021]
- **Previous COVID-19 forecasts: cases** [04-14-2021]
- **COVID-19 forecasts: cases** [04-14-2021]
- **Previous COVID-19 forecasts: hospitalizations** [04-14-2021]
- **COVID-19 forecasts: hospitalizations** [04-14-2021]
- **Previous forecasts of total deaths** [04-14-2021]
- **COVID-19 forecasts: deaths** [04-14-2021]
- **Percent of delivered first vaccine doses administered by U.S. States and Territories** [04-12-2021]
• Importance of COVID-19 vaccination for residents of long-term care facilities [04-12-2021]
• FDA media briefing: Janssen COVID-19 vaccine [04-13-2021]
• Joint CDC and FDA statement on Johnson & Johnson COVID-19 vaccine [04-13-2021]
• Information about Johnson & Johnson’s Janssen COVID-19 vaccine [04-13-2021]
• Selected adverse events reported after COVID-19 vaccination [04-13-2021]

ECDC: European Centre for Disease Prevention and Control | ecdc.europa.eu
• Situation update for EU/EEA
  o As of week 2021-14, 28 496 538 cases and 645 412 deaths have been reported in the EU/EEA
  o As of week 2021-13, 27 513 674 cases and 627 242 deaths have been reported in the EU/EEA
• Communicable disease threats report, 4-10 April 2021, week 14 [04-09-2021]
• Reinfection with SARS-CoV-2: implementation of a surveillance case definition within the EU/EEA [04-08-2021]
• Download data for the maps in support of the Council Recommendation on a coordinated approach to the restriction of free movement in response to the COVID-19 pandemic in the EU/EEA and the UK [updated regularly]
• Data on country response measures to COVID-19 [updated regularly]
• Data on the daily number of new reported COVID-19 cases and deaths by EU/EEA country [updated regularly]
• Download data on hospital and ICU admission rates and current occupancy for COVID-19 [updated regularly]
• Download data on the daily subnational 14-day notification rate of new COVID-19 cases [updated regularly]
• Data on the weekly subnational 14-day notification rate of new COVID-19 cases [updated regularly]
• Download data on testing for COVID-19 by week and country [updated regularly]
• Download data on 14-day notification rate of new COVID-19 cases and deaths [updated regularly]
• Download the daily number of new reported cases of COVID-19 by country worldwide [updated regularly]

FDA: U.S. Food & Drug Administration | fda.gov
• Coronavirus (COVID-19) update: daily roundup [updated regularly]
• Joint CDC and FDA statement on Johnson & Johnson COVID-19 vaccine [04-13-2021]
• Vaccine ready: addressing COVID-19 health disparities among racial and ethnic minority communities [04-12-2021]
• Coronavirus (COVID-19) update: FDA issues emergency use authorization for the Symbiotica COVID-19 self-collected antibody test system [04-06-2021]
• FDA in brief: FDA provides update on COVID-19 Pandemic Recovery and Preparedness Plan initiative [04-02-2021]
Coronavirus (COVID-19) update: FDA makes two revisions to Moderna COVID-19 vaccine emergency use authorization to help increase the number of vaccine doses available [04-01-2021]

Public Health England | gov.uk
- Confirmed cases of COVID-19 variants identified in UK [updated 04-15-2021]
- COVID-19: infection prevention and control (IPC) [updated 04-15-2021]
- COVID-19 variants: genometrically confirmed case numbers [updated 04-15-2021]
- National protocol for COVID-19 Vaccine AstraZeneca (ChAdOx1-S [recombinant]) [updated 04-14-2021]
- COVID-19: reported SARS-CoV-2 deaths in England [updated 04-14-2021]
- COVID-19 vaccination and blood clotting [updated 04-13-2021]
- National protocol for COVID-19 mRNA vaccine BNT162b2 (Pfizer/BioNTech) [updated 04-13-2021]

World Health Organization | who.int
- WHO Director-General’s opening remarks at the Member State Information Session on COVID-19 [04-15-2021]
  - “WHO does not want endless lockdowns. We all want to see societies and economies reopening, and travel and trade resuming. We have the tools in hand to control the pandemic, but every country must apply them consistently. We urge all Member States to implement a tailored, measured, agile and evidence-based combination of measures, including surveillance, testing, contact tracing, supportive quarantine and compassionate care. And we must continue to encourage people to take the personal precautions to keep themselves and others safe: physical distancing, masks, hand hygiene and ventilation. We may sound like a broken record, but these measures work. So many countries have shown that this virus can be stopped with proven public health measures and strong systems that respond comprehensively, rapidly and consistently.
  - Vaccines are a powerful tool, but vaccines alone will not end the pandemic.”
- Director-General’s opening remarks at 7th COVID-19 Emergency Committee [04-15-2021]
- WHO COVID-19 essential supplies forecasting tool (COVID-ESFT) [04-14-2021]
- COVID-19 and vaccine equity panel: what can the World Trade Organization contribute? [04-14-2021]
- Coronavirus disease (COVID-19) weekly epidemiological update [04-13-2021]
- Benefits of continuing to provide life-saving HIV services outweigh the risk of COVID-19 transmission by 100 to 1 [04-13-2021]
- COVAX reaches over 100 economies, 42 days after first international delivery [04-08-2021]
- Reducing public health risks associated with the sale of live wild animals of mammalian species in traditional food markets [04-12-2021]
- Coronavirus disease (COVID-19) weekly operational update [04-12-2021]
- Safe Ramadan practices in the context of COVID-19 [04-07-2021]
- Interim statement of the COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety on AstraZeneca COVID-19 vaccine [04-07-2021]
- Log of major changes and errata in WHO daily aggregate case and death count data [updated regularly]
- Draft landscape and tracker of COVID-19 candidate vaccines [updated regularly]
Other relevant government bodies / health care organizations

- **Ontario Government**
  - Ontario moves schools to remote learning following spring break [04-12-2021]
  - Ontario expands COVID-19 vaccination locations to more pharmacies [04-11-2021]

- **Health Canada**
  - Government of Canada establishes Critical Drug Reserve to bolster Canada’s supply of drugs used to treat COVID-19 [04-14-2021]
  - Health Canada provides update on safety review of AstraZeneca and COVISHIELD COVID-19 vaccines [04-14-2021]

- **Statistics Canada**
  - COVID-19: a data perspective [updated regularly]
  - Canadians' well-being in year one of the pandemic [04-15-2021]
  - COVID-19 mortality rates were higher for people living in apartments and larger households [04-13-2021]
  - People living in apartments and larger households were at higher risk of dying from COVID-19 during the first wave of the pandemic [04-13-2021]
  - Detailed preliminary data on confirmed cases of COVID-19, January 15, 2020, to April 4, 2021 (revised data) [04-09-2021]

- **Indigenous Services Canada**

- **UK Department of Health and Social Care**
  - Face coverings: when to wear one, exemptions, and how to make one [updated 04-15-2021]
  - Making a childcare bubble with another household [updated 04-15-2021]
  - Consultation launched on staff COVID-19 vaccines in care homes with older adult residents [04-14-2021]
  - Making vaccination a condition of deployment in older adult care homes [04-14-2021]
  - UK moves into next phase of vaccine roll-out as government target hit early [04-13-2021]
  - Priority groups for phase 2 of the coronavirus (COVID-19) vaccination programme: advice from the JCVI [updated 04-13-2021]

- **UK Scientific Advisory Group for Emergencies (SAGE)**
  - ONS: Differential impacts of the Coronavirus pandemic on men and women, 24 March 2021 [04-09-2021]
  - COVID-19 Ethnicity subgroup: Interpreting differential health outcomes among minority ethnic groups in wave 1 and 2, 24 March 2021 [04-09-2021]
  - UKOSS/ISARIC/CO-CIN: Females in Hospital with SARS-CoV-2 infection, the association with pregnancy and pregnancy outcomes, 25 March 2021 [04-09-2021]
• UK Office for National Statistics
  o Coronavirus and the social impacts on disabled people in Great Britain: February 2021 [04-09-2021]
• UK Ministry of Housing, Communities & Local Government
  o COVID-19: guidance for the safe use of places of worship and special religious services and gatherings during the pandemic [04-09-2021]
• UK Ofsted
  o Ofsted guidance and information relating to coronavirus (COVID-19) for schools, early years, children's social care and further education and skills providers [updated 03-29-2021]

Research Institutes

Centre for Global Infectious Disease Analysis | imperial.ac.uk/mrc-global-infectious-disease-analysis/
  • Report 43 - Quantifying the impact of vaccine hesitancy in prolonging the need for non-pharmaceutical interventions to control the COVID-19 pandemic [03-24-2021]

CIDRAP: Center for Infectious Disease Research Policy | cidrap.umn.edu
  • US advisers recommend J&J COVID vaccine stay on pause [04-14-2021]
  • Exercise may strongly protect against poor COVID-19 outcomes [04-14-2021]
  • Global COVID-19 cases, deaths continue steady rise [04-14-2021]
  • COVID-19 Scan for Apr 14, 2021: Airline seating and COVID spread; Suicide during pandemic; MIS-C post-COVID-19
  • US halts J&J COVID vaccine after reports of blood clots [04-13-2021]
  • Newborns of COVID-vaccinated moms may be protected from infection [04-13-2021]
  • Vaccine probes, COVID-19 surges shuffle vaccine rollout in some nations [04-13-2021]

National Collaborating Centre for Environmental Health | ncceh.ca
  • March, 2021 Environmental Health Research Scan (with COVID-19 section)
  • February, 2021 Environmental Health Research Scan (with COVID-19 section)
  • January, 2021 Environmental Health Research Scan (with COVID-19 section)
  • December Environmental Health Research Scan (with COVID-19 section)
  • November Environmental Health Research Scan (with COVID-19 section)
  • October Environmental Health Research Scan (with COVID-19 section)

ProMED | promedmail.org
  • Latest on COVID-19 [individual posts]
  • COVID-19 update (134): adenovector-based vaccines, superspreader events, WHO [04-15-2021]
Updated Daily

COVID-19 resources (case counts) | arcgis.com
- Canada COVID-19

COVID-19 Canada Open Data Working Group | COVID-19 CODWG
- COVID-19 in Canada (case count dashboard)

Johns Hopkins CCSE | systems.jhu.edu
- 2019-nCoV Global Cases (by Johns Hopkins CSSE) [real-time tracking]
- Resetting our response: changes needed in the US approach to COVID-19 [07-29-2020]

NextStrain | nextstrain.org
- Phylogeny of SARS-like betacoronaviruses including novel coronavirus (nCoV) [real-time tracking]
- Genomic epidemiology of novel coronavirus (nCoV) [real-time tracking]
- Genomic analysis of nCoV spread. Situation report 2020-01-30 [real-time tracking]

Guidelines and Technical documents (updated weekly)
The guidelines listings were last updated 04-07-2021

Section I: General Guidelines

Ontario / Canada Main Page
- Ontario guidance
- Canadian guidance (federal)

Case Definitions/Background Information

Ontario Ministry of Health
- Ontario case definition - Coronavirus Disease (COVID-19) [updated 02-18-2021]

PHAC
- National case definition: Coronavirus disease (COVID-19) [updated 03-08-2021]
- COVID-19 case report form [updated 02-15-2021]

WHO
• Considerations for implementing and adjusting public health and social measures in the context of COVID-19 [11-04-2020]
• Considerations in the investigation of cases and clusters of COVID-19: interim guidance [10-22-2020]
• WHO COVID-19 Preparedness and Response Progress Report - 1 February to 30 June 2020 [08-03-2020]

CDC
• Coronavirus disease 2019 (COVID-19) 2020 interim case definition, approved August 5, 2020 [08-05-2020]

ECDC
• Data on country response measures to COVID-19 [03-25-2021]
• Rapid risk assessment: increased transmission of COVID-19 in the EU/EEA and the UK – thirteenth update [10-23-2020]

UK
• COVID-19: background information [updated regularly]
• COVID-19: epidemiology, virology and clinical features [updated regularly]

Australia
• What you need to know about coronavirus (COVID-19) [updated regularly]

Other
• BMJ Best Practice COVID-19 [updated regularly]

Laboratories

Ontario Ministry of Health
• COVID-19 Provincial testing guidance update V. 11 [03-05-2021]
• Community labs and specimen collection centres: version 3 [03-29-2020]

PHAC
• Biosafety advisory: SARS-CoV-2 (severe acute respiratory syndrome-related coronavirus 2) [modified 11-26-2020]
• National polymerase chain reaction (PCR) testing indication guidance for COVID-19 [modified 10-07-2020]
• Requirements for serological antibody tests submitted under the COVID-19 interim order: guidance [updated 04-28-2020]

WHO
• Operational considerations to expedite genomic sequencing component of GISRS surveillance of SARS-CoV-2 [03-30-2021]
• Laboratory biosafety guidance related to coronavirus disease (COVID-19): Interim guidance, 28 January 2021 [01-28-2021]
• Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health [01-08-2021]
- SARS-CoV-2 genomic sequencing for public health goals: Interim guidance, 8 January 2021 [01-08-2021]
- SARS-CoV-2 antigen-detecting rapid diagnostic tests: An implementation guide [12-21-2020]
- Assessment tool for laboratories implementing SARS-CoV-2 testing [10-23-2020]
- Diagnostic testing for SARS-CoV-2: interim guidance [09-11-2020]
- Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays: interim guidance [09-11-2020]

CDC

- Resources for laboratories working on coronavirus (COVID-19) [03-28-2021]
- Information for laboratories about coronavirus (COVID-19) [updated 03-28-2021]
- Evaluation for SARS-CoV-2 Testing in Animals [updated 03-22 2021]
- Interim guidelines for COVID-19 antibody testing: interim guidelines for COVID-19 antibody testing in clinical and public health settings [updated 03-17-2021]
- Guidance for SARS-CoV-2 point-of-care testing [03-12-2021]
- Frequently asked questions on COVID-19 testing for laboratories [updated 03-10-2021]
- Interim guidelines for collecting, handling, and testing clinical specimens for COVID-19 [updated 02-26-2021]
- How to report COVID-19 laboratory data [updated 01-26-2021]
- Interim laboratory biosafety guidelines for handling and processing specimens associated with coronavirus disease 2019 (COVID-19) [updated 01-06-2021]
- SARS-CoV-2 viral culturing at CDC [updated 12-29-2020]
- Using antibody tests for COVID-19 [updated 11-03-2020]
- Serology testing for COVID-19 at CDC [updated 11-03-2020]
- Guidance for general laboratory safety practices during the COVID-19 pandemic [08-24-2020]

UK

- Maintaining records of staff, customers and visitors to support NHS Test and Trace [updated 04-05-2021]
- Surge testing for new coronavirus (COVID-19) variants [updated 04-01-2021]
- NHS test and trace statistics (England): methodology [updated 04-01-2021]
- COVID-19: guidance for sampling and for diagnostic laboratories [updated 03-29-2021]
- How tests and testing kits for coronavirus (COVID-19) work: the different types of tests and testing kits for COVID-19, and the specifications for manufacturers [updated 03-23-2021]

Australia

- PHLN guidance on laboratory testing for SARS-CoV-2 (the virus that causes COVID-19) [updated 02-24-2021]

Other

- PHO order on health authority regulated health professionals SARS-CoV-2 swabbing – British Columbia [11-16-2020]
• PHO order on midwives and certified practice speech language pathologists SARS-CoV-2 swabbing – British Columbia [11-16-2020]
• PHO Order on British Columbia emergency health services SARS-CoV-2 swabbing – British Columbia [11-16-2020]

Public Health
General Guidelines

PHAC
• COVID-19 and people with disabilities in Canada [modified 02-09-2021]
• COVID-19: Safety advice for private indoor gatherings [modified 11-23-2020]
• Community-based measures to mitigate the spread of coronavirus disease (COVID-19) in Canada [updated 10-15-2020]
• Federal/provincial/territorial public health response plan for ongoing management of COVID-19 [modified 08-25-2020]

Canadian provinces and territories (other than Ontario)
• BC COVID-19 Ethical Decision-Making Framework [12-24-2020]
• BC Interim guidance: public health management of cases and contacts associated with novel coronavirus (COVID-19) in the community [updated 09-25-2020]

WHO
• WHO-convened global study of origins of SARS-CoV-2: China Part [03-30-2021]
• COVID-19 new variants: Knowledge gaps and research [03-25-2021]
• Definition and categorization of the timing of mother-to-child transmission of SARS-CoV-2 [02-07-2021]
• Considerations in adjusting public health and social measures in the context of COVID-19: interim guidance [11-04-2020]
• Considerations for quarantine of contacts of COVID-19 cases [08-19-2020]
• Home care for patients with suspected or confirmed COVID-19 and management of their contacts: Interim guidance [08-12-2020]
• Practical actions in cities to strengthen preparedness for the COVID-19 pandemic and beyond [07-17-2020]
• Investing in and building longer-term health emergency preparedness during the COVID-19 pandemic [07-06-2020]
• Considerations on Indigenous Peoples, Afro-Descendants, and Other Ethnic Groups during the COVID-19 Pandemic, 4 June 2020 [06-04-2020]
• Policy Brief: COVID-19 and People on the Move [06-00-2020]

CDC
• Public health guidance for potential COVID-19 exposure associated with international travel or cruise travel [updated 04-02-2021]
• Genomic Surveillance for SARS-CoV-2 Variants [updated 04-02-2021]
• Evidence used to update the list of underlying medical conditions that increase a person’s risk of severe illness from COVID-19 [updated 03-29-2021]
• RRT composition: COVID-19 considerations [updated 03-01-2021]
• Public health guidance for community-related exposure [updated 03-01-2021]
• Discontinuation of isolation for persons with COVID-19 not in healthcare settings: interim guidance [updated 02-18-2021]
• Criteria for return to work for healthcare personnel with suspected or confirmed COVID-19 (interim guidance) [updated 02-16-2021]
• Interim guidance for implementing home care of people not requiring hospitalization for coronavirus disease 2019 (COVID-19) [updated 10-16-2020]
• Wildfire smoke and COVID-19: frequently asked questions and resources for air resource advisors and other environmental health professionals [updated 10-09-2020]
• Managing investigations during an outbreak [updated 07-31-2020]
• Optimizing Supply of PPE and Other Equipment during Shortages [updated 07-16-2020]

ECDC
• One-day in-action review (IAR) protocol in the context of COVID-19 [03-00-2021]
• COVID-19 – high risk shielded patient list identification methodology [updated 03-00-2021]
• Behavioural Insights research to support the response to COVID-19: a survey of implementation in the EU/EEA [02-17-2021]
• Conducting in-action and after-action reviews of the public health response to COVID-19 [06-04-2020]

Australia
• CDNA National guidelines for public health units [updated 03-04-2021]

Other
• Public health ethics and COVID-19: selected resources – National Collaborating Centre for Healthy Public Policy [updated 03-30-2021]
• Public health ethics and Covid-19: selected websites – National Collaborating Centre for Healthy Public Policy [updated 10-00-2020]

Back to Top

Data & Surveillance
Canada
• COVID-19 epidemiological and economic research data [modified 04-01-2021]
• Mathematical modelling and COVID-19 [03-26-2021]
• National surveillance guidelines for coronavirus disease (COVID-19) [modified 03-19-2021]

WHO
• Public health surveillance for COVID-19: interim guidance [12-16-2020]
• Corrigenda – Maintaining surveillance of influenza and monitoring SARS-CoV-2 [12-03-2020]
• Maintaining surveillance of influenza and monitoring SARS-CoV-2 – adapting Global Influenza surveillance and Response System (GISRS) and sentinel systems during the COVID-19 pandemic [11-19-2020]
• WHO COVID-19 Essential Supplies Forecasting Tool (ESFT) [08-26-2020]
• Status of environmental surveillance for SARS-CoV-2 virus – scientific brief [08-07-2020]
• Global surveillance of COVID-19: WHO process for reporting aggregated data [08-07-2020]
• Estimating mortality from COVID-19 [08-04-2020]
• Surveillance strategies for COVID-19 human infection. Update 29 [06-05-2020]
• Surveillance protocol for SARS-CoV-2 infection among health workers [05-28-2020]

CDC
• National wastewater surveillance system (NWSS) [updated 03-19-2021]
• COVID-19 serology surveillance [updated 03-11-2021]
• Data visualization [updated 02-16-2021]
• Wastewater surveillance data reporting & analytics [updated 01-27-2021]
• Targeted wastewater surveillance at facilities, institutions, and workplaces [updated 11-23-2020]
• Developing a wastewater surveillance sampling strategy [updated 11-23-2020]
• Wastewater surveillance testing methods [updated 11-23-2020]
• Public health interpretation and use of wastewater surveillance data [updated 11-23-2020]
• Large-scale geographic seroprevalence surveys [updated 10-02-2020]

Public Health England
• COVID-19 surveillance in school KIDs (sKIDs): pre and primary schools [09-04-2020]

Testing
Canada
• Interim guidance on the use of rapid antigen detection tests for the identification of SARS-CoV-2 infection [02-23-2021]
• Guidance for repeated PCR testing in individuals previously positive for COVID-19 [12-08-2020]
• National polymerase chain reaction (PCR) testing indication guidance for COVID-19 [10-07-2020]
• Pan-Canadian COVID-19 testing and screening guidance: technical guidance and implementation plan [10-07-2020]
Ontario Ministry of Health

- Point-of-Care Testing Use Case Guidance Version 4.0 [03-23-2021]
- Considerations for Antigen Point-of-Care Testing. Version 4.0 [03-19-2021]
- COVID-19 quick reference public health guidance on testing and clearance: version 13 [updated 03-05-2021]
- COVID-19 provincial testing guidance: version 11.0 [03-05-2021]
- Considerations for privately-initiated testing. Version 2.0 [03-05-2021]
- Considerations for rapid antigen screening pilot [11-20-2020]
- COVID-19 Variant of Concern: Case, Contact and Outbreak Management Interim Guidance. Version 2.0 [02-26-2021]
- Rapid Point of Care Testing Use Case Guidance. V. 2 [02-19-2021]
- COVID-19 Guidance: Considerations for Rapid Antigen Screening. Version 2.0 [02-17-2021]

Canadian provinces and territories (other than Ontario)

- BC Infection prevention and control guidance for test collection and assessment centres [03-09-2021]
- BC Antibody testing (serology) page [no date]
- BC Information for health care providers on testing asymptomatic individuals for COVID-19 [08-20-2020]
- BC Guideline for the appropriate use of SARS-CoV-2 (COVID-19) antibody (serology) testing [08-14-2020]

CDC

- Performing Broad-Based Testing for SARS-CoV-2 in Congregate Correctional, Detention, and Homeless Service Settings [03-29-2021]
- Overview of Testing for SARS-CoV-2 (COVID-19) [03-17-2021]
- Interim guidance for SARS-CoV-2 testing in correctional and detention facilities [updated 03-17-2021]
- Guidance for SARS-CoV-2 point-of-care and rapid testing [updated 03-12-2021]
- Testing Strategies for SARS-CoV-2 [updated 03-11-2021]
- Interim Guidance on Testing Healthcare Personnel for SARS-CoV-2 [updated 02-16-2021]
- Considerations for use of SARS-CoV-2 antigen testing in nursing homes [updated 01-07-2021]
- Testing guidelines for nursing homes: interim SARS-CoV-2 testing guidelines for nursing home residents and healthcare personnel [updated 01-07-2021]
- Interim Guidance for Rapid Antigen Testing for SARS-CoV-2 [updated 12-16-2020]
- CDC’s diagnostic test for COVID-19 only and supplies [updated 12-09-2020]
- Interim Considerations for Testing for K-12 School Administrators and Public Health Officials [updated 12-04-2020]
• Guidance for health departments about COVID-19 testing in the community [updated 12-01-2020]
• Using antibody tests for COVID-19 [updated 11-03-2020]
• Serology testing for COVID-19 at CDC [updated 11-03-2020]
• CDC Diagnostic Tests for COVID-19 [updated 08-05-2020]

UK
• Investigation of novel SARS-CoV-2 variant: variant of concern 202012/01 [updated 04-01-2021]
• SARS-CoV-2 RNA testing: assurance of positive results during periods of low prevalence [updated 10-16-2020]

ECDC
• Considerations on the use of self-tests for COVID-19 in the EU/EEA [03-17-2021]
• Guidance for COVID-19 quarantine and testing of travellers [03-12-2021]
• Methods for the detection and identification of SARS-CoV-2 variants [03-03-2021]
• Detection and characterisation capability and capacity for SARS-CoV-2 variants within the EU/EEA [02-16-2021]
• Risk assessment: SARS-CoV-2 - increased circulation of variants of concern and vaccine rollout in the EU/EEA, 14th update [02-15-2021]
• Options for the use of rapid antigen tests for COVID-19 in the EU/EEA and the UK [11-19-2020]
• COVID-19 testing strategies and objectives [09-19-2020]
• Objectives for COVID-19 testing in school settings [08-10-2020]

AUS
• PHLN guidance on laboratory testing for SARS-CoV-2 (the virus that causes COVID-19) [last updated 02-24-2021]
• PHLN and DCNA joint statement on SARS-CoV-2 rapid antigen tests [updated 10-09-2020]

Symptoms/Treatment
Canada
• COVID-19 signs, symptoms and severity of disease: a clinician guide [modified 02-17-2021]
• COVID-19 for health professionals: Treatments [modified 02-15-2021]
• Non-contact infrared thermometers (NCIT) (modified 01-28-2021)

Ontario Ministry of Health
• COVID-19 Signage Questions for Businesses and Organizations, Version 2 [02-26-2021]
• COVID-19 reference document for symptoms v. 7.0 [09-21-2020]
• COVID-19 Patient Screening Guidance Document version 4 [06-11-2020]

Canadian provinces and territories (other than Ontario)
• BC Clinical reference group SBAR: therapies for COVID-19 [updated 03-19-2021]
• BC Antimicrobial and immunomodulatory therapy in adult patients with COVID-19 [updated 03-19-2021]
• BC COVID-19 Therapeutic Committee recommendation: therapies for COVID-19 [updated 03-19-2021]
• BC Pediatric clinical guidance for COVID-19 [updated 03-11-2021]
• BC Multisystem inflammatory syndrome in children (MIS-C) temporally associated with COVID-19: guidance for clinicians in B.C. [12-08-2020]
• BC Guideline for the management of the neonate in the NICU, nursery of pediatric unit that is a confirmed or suspect case of COVID-19 [09-04-2020]
• QC COVID-19 symptom-based screening questionnaire [02-17-2021]

CDC
• Screening K-12 students for symptoms of COVID-19: limitations and considerations [03-17-2021]
• Interim Guidance on Duration of Isolation and Precautions for Adults with COVID-19 [updated 02-17-2021]
• Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19) [updated 02-13-2021]
• Assessing risk factors for severe COVID-19 illness [updated 11-30-2020]

WHO
• Therapeutics and COVID-19: living guideline [03-31-2021]
• COVID-19 Clinical management: living guidance [01-25-2021]

U.S. NIH
• COVID-19 Treatment guidelines [updated 03-05-2021]

Public Health England
• SARS-CoV-2 VOC and VUI: investigating and managing individuals with a possible or confirmed case [updated 03-15-2021]

AUS
• Australian guidelines for the clinical care of people with COVID-19. v. 36 [last updated 03-31-2021]
• Coronavirus (COVID-19) – identifying the symptoms [last updated 11-09-2020]

Case Investigation & Contact Tracing
Canada
• Public health management of cases and contacts associated with COVID-19 [updated 02-25-2021]

Ontario
• Appendix 9: Management of Individuals with Point-of-Care Results Version 4.0 [03-23-2021]
• COVID-19 Variant of Concern: Case, Contact and Outbreak Management Interim Guidance version 2.0 [02-26-2021]
Appendix 8: Cases with Positive COVID-19 Serology Results and Management of Cases with Multisystem Inflammatory Syndrome in Children (MIS-C) Temporally Associated with COVID-19 [02-18-2021]

Management of cases and contacts of COVID-19 in Ontario version 11.0 [01-12-2021]

Appendix 10: Case & Contact Management COVID-19 Surge Support Model (Pilot) [01-21-2021]

WHO

- Contact tracing in the context of COVID-19 [02-01-2021]
- Online global consultation on contact tracing for COVID-19, 9-11 June 2020 [01-22-2021]
- Ethical considerations to guide the use of digital proximity tracking technologies for COVID-19 contact tracing [05-28-2020]
- Considerations in the investigation of cases and clusters of COVID-19 [04-02-2020]

CDC

- Operational Considerations for Adapting a Contact Tracing Program to Respond to the COVID-19 Pandemic [updated 03-05-2021]
- Operational considerations for adapting a contact tracing program to respond to the COVID-19 pandemic [03-05-2021]
- COVID-19 Contact Tracing Communications Toolkit for Health Departments [updated 03-02-2021]
- Contact tracing resources for Health Departments [updated 03-01-2021]
- Notification of exposure: a contact tracer’s guide for COVID-19 [updated 02-26-2021]
- Contact Tracing for COVID-19 [updated 02-25-2021]
- Prioritizing Case Investigations and Contact Tracing for COVID-19 in High Burden Jurisdictions [updated 02-19-2021]
- Interim Guidance on Developing a COVID-19 Case Investigation & Contact Tracing Plan: Overview [updated 02-18-2021]
- Scaling Up Staffing Roles in Case Investigation and Contact Tracing [updated 12-03-2020]
- Prioritizing COVID-19 Contact Tracing Mathematical Modeling Methods and Findings [updated 11-23-2020]
- Investigating a COVID-19 Case [updated 11-23-2020]
- Contact tracing: frequently asked questions for health departments [updated 10-21-2020]
- Digital Contact Tracing Tools [updated 05-26-2020]

Public Health England

- COVID-19: guidance for households with possible coronavirus infection [updated 03-30-2021]
- Guidance for contacts of people with confirmed coronavirus (COVID-19) infection who do not live with the person [updated 03-30-2021]

UK

- COVID-19: investigation and initial clinical management of possible cases [updated 12-14-2020]

ECDC
• Contact tracing: public health management of persons, including healthcare workers, who have had contact with COVID-19 cases in the European Union – third update [11-18-2020]
• Considerations relating to passenger locator data, entry and exit screening and health declarations in the context of COVID-19 in the EU/EEA and the UK [06-12-2020]
• Mobile applications in support of contact tracing for COVID-19 - A guidance for EU EEA Member States [06-10-2020]

Infection Prevention and Control

PHAC / Health Canada
• Coronavirus disease (COVID-19): Prevention and risks [modified 03-22-2021]
• Infection Prevention and Control for COVID-19: Interim Guidance for Home Care Settings [modified 03-18-2020]
• Infection prevention and control for COVID-19. Second interim guidance for acute healthcare settings [modified 02-12-2021]
• COVID-19 medical masks and N95 respirators: Overview [modified 01-29-2021]
• COVID-19: Guidance on indoor ventilation during the pandemic [modified 01-18-2021]
• Evaluating COVID-19 disease transmission and public health measures in schools: Outbreak investigation guidance [11-16-2020]
• Federal/provincial/territorial public health response plan for ongoing management of COVID-19 [modified 08-25-2020]
• Infection prevention and control for COVID-19: Interim guidance for outpatient and ambulatory care settings [modified 05-23-2020]

Ontario
• Infection Prevention and Control Hubs [11-10-2020]

Canadian provinces and territories (other than Ontario)
• BC PPE audit tool [03-19-2021]
• BC Discussion on risk of SARS-CoV-2 aerosol transmission in health care settings [03-05-2021]
• BC Infection Prevention and Control (IPC) Protocol during In-Hospital Code Blue for Adult Patients [01-20-2021]
• BC COVID-19: personal protective equipment recommendations for endotracheal intubation of suspected or confirmed COVID-19 patients in critical care and emergency departments [updated 01-14-2021]
• QC COVID-19: collection, disinfection and storage processes for single-use N95 filtering facepiece respirators [12-21-2020]

WHO
• WHO Living guideline: Drugs to prevent COVID-19 [03-02-2021]
- Roadmap to improve and ensure good indoor ventilation in the context of COVID-19 [03-01-2021]
- COVID-19: Occupational health and safety for health workers [02-02-2021]
- Water, sanitation, hygiene, and waste management for SARS-CoV-2, the virus that causes COVID-19 [07-29-2020]
- Infection prevention and control during health care when coronavirus disease (COVID-19) is suspected or confirmed [06-29-2020]

CDC
- Guidance for Cleaning and Disinfecting Public Spaces, Workplaces, Businesses, Schools, and Homes [updated 04-05-2021]
- Cleaning and Disinfection for Community Facilities: Interim Recommendations for U.S. Community Facilities with Suspected/Confirmed Coronavirus Disease 2019 (COVID-19) [updated 04-05-2021]
- Interim Infection Prevention and Control Recommendations to Prevent SARS-CoV-2 Spread in Nursing Homes [updated 03-29-2021]
- Preparing for COVID-19 in Nursing Homes [updated 03-29-2021]
- Cleaning, Disinfection, and Hand Hygiene in Schools: A Toolkit for School Administrators [updated 02-22-2021]
- Strategies for Optimizing the Supply of N95 Respirators [updated 02-10-2021]
- Strategies for Optimizing the Supply of Eye Protection [12-22-2020]
- Considerations for Inpatient Obstetric Healthcare Settings [updated 12-01-2020]
- Guidance for pharmacies: Guidance for Pharmacists and Pharmacy Technicians in Community [updated 11-13-2020]
- Considerations for optimizing the supply of powered air-purifying respirators (PAPRs) [updated 11-03-2020]
- Implementing Filtering Facepiece Respirator (FFR) Reuse, Including Reuse after Decontamination, When There Are Known Shortages of N95 Respirators [updated 10-19-2020]
- Considerations for Release of Stockpiled N95s Beyond the Manufacturer-Designated Shelf Life [updated 07-20-2020]
- Optimizing Personal Protective Equipment (PPE) Supplies [updated 07-16-2020]

ECDC
- Risk of SARS-CoV-2 transmission from newly-infected individuals with documented previous infection or vaccination [03-29-2021]
- Infection prevention and control and preparedness for COVID-19 in healthcare settings - sixth update [02-09-2021]
- Coronavirus disease 2019 (COVID-19) and supply of substances of human origin in the EU/EEA - Second update [12-10-2020]
- COVID-19 infection prevention and control for primary care, including general practitioner practices, dental clinics and pharmacy settings [10-19-2020]
- Guidelines for the use of non-pharmaceutical measures to delay and mitigate the impact of 2019-nCoV [09-24-2020]
- Options for the decontamination and reuse of respirators in the context of the COVID-19 pandemic [06-08-2020]

UK
- Technical Specifications for Personal Protective Equipment (PPE) [updated 04-01-2021]
- Ventilation of indoor spaces to stop the spread of coronavirus (COVID-19) [updated 03-24-2021]
- COVID-19: guidance for stepdown of infection control precautions and discharging COVID-19 patients from hospital to home settings [updated 03-22-2021]
- COVID-19: infection prevention and control (IPC) [updated 01-21-2021]
- COVID-19: personal protective equipment use for aerosol generating procedures [updated 08-21-2020]
- COVID-19: personal protective equipment use for non-aerosol generating procedures [updated 08-21-2020]

Australia
- Guidance on the use of personal protective equipment (PPE) in hospitals during the COVID-19 outbreak [updated 11-12-2020]

Reopening Guidelines

Ontario
- ON COVID-19 response framework: keeping Ontario safe and open [updated 04-01-2021]
- ON Reopening Ontario after COVID-19 [updated 01-19-2021]

Canada (federal) and provinces and territories (other than Ontario)
- CA Guidance for a strategic approach to lifting restrictive public health measures [updated 05-30-2020]
- BC BC COVID-19 go-forward management strategy [no date]
- AB Alberta’s Relaunch Strategy [no date]
- SK Re-open Saskatchewan plan [no date]
• MB Restoring safe services: Manitoba’s pandemic and economic roadmap for recovery [no date]
• QC Map of COVID-19 alert levels by region [no date]
• NB Public Health Guidance [no date]
• NL Alert level system [no date]
• PEI Renew PEI together [no date]
• NS COVID-19 restriction updates [updated regularly]
• NW Emerging Wisely – Path to Eased Public Health Restrictions [modified 12-18-2020]
• YT Plan for lifting Yukon’s COVID-19 restrictions [no date]
• NT Nunavut’s Path: moving forward during COVID-19 [no date]
• Guidance on Re-Opening Northern, Remote, Isolated, and Indigenous Communities [06-30- 2020]

WHO
• Considerations for implementing and adjusting public health and social measures in the context of COVID-19 [11-04-2020]

UK
• Reopening businesses and venues in England [updated 03-29-2021]
• Coronavirus (COVID-19): guidance on the phased return of elite sport [updated 03-10-2021]
• Our plan to rebuild: the UK government’s COVID-19 recovery strategy [updated 07-24-2020]

ECDC
• Introducing a coherent European framework for tuning COVID-19 response measures [03-17-2021]

Vaccinations
Ontario Ministry of Health
• COVID-19 Vaccine-relevant information and planning resources [updated 03-30-2021]
• Ethical framework for COVID-19 vaccine distribution [updated 01-11-2021]

Canada
• Vaccines for COVID-19: Authorized vaccines [modified 03-23-2021]
• Recommendations on the use of COVID-19 vaccine(s) [modified 03-19-2021]
• Health Care Provider Vaccine Tool Kit [no date]
• Guidance on the prioritization of key populations for COVID-19 immunization [modified 02-12-2021]
• Webinars on COVID-19 vaccines [modified 02-15-2021]
• Planning guidance for administration of COVID-19 vaccine [12-21-2020]
• Planning guidance for immunization clinics for COVID-19 vaccines [12-21-2020]
• Guidance on the prioritization of initial doses of COVID-19 vaccine(s) [12-18-2020]
• Canada’s COVID-19 immunization plan: saving lives and livelihoods [12-05-2020]
• COVID-19 immunization: federal, provincial and territorial statement of common principles [11-12-2020]
• Preliminary guidance on key populations for early COVID-19 immunization [11-03-2020]
• Guidance for influenza vaccine delivery in the presence of COVID-19 [08-05-2020]
• Interim guidance on continuity of immunization programs during the COVID-19 pandemic [modified 05-13-2020]

Canada (federal) and provinces and territories (other than Ontario)
• BC COVID-19 vaccine information for people who are clinically extremely vulnerable [04-06-2021]
• BC COVID-19 vaccine planning guide for people who are pregnant or breastfeeding [03-26-2021]
• BC Clinical Guidance on COVID-19 Vaccines for People with Splenectomy or Functional Asplenia [03-18-2021]
• BC Clinical Guidance on COVID-19 Vaccines for Persons with Inflammatory Bowel Disease [03-18-2021]
• BC Clinical Guidance on COVID-19 Vaccines for Persons with Autoimmune Rheumatic Diseases [03-19-2021]
• BC Clinical Guidance on COVID-19 Vaccines for People with Solid Cancers [03-16-2021]
• BC Clinical Guidance on COVID-19 Vaccines for People with Hematological Malignancy [03-16-2021]
• BC Clinical Guidance on COVID-19 Vaccines for People with Autoimmune Neuromuscular Disorders Receiving Immunosuppressive/Immunomodulating Therapy [03-13-2021]
• BC Clinical Guidance on COVID-19 Vaccines for People with Significant Neuromuscular Conditions Who Require Respiratory Support [03-09-2021]

WHO
• Evaluation of COVID-19 vaccine effectiveness: interim guidance, 17 March 2021 [03-17-2021]
• Sample size calculator for evaluation of COVID-19 vaccine effectiveness (Excel) [03-17-2021]
• Interim recommendations for the use of the Janssen Ad26.COVID-19 [03-17-2021]
• How to monitor and report COVID-19 vaccine side effects [03-15-2021]
• Monitoring COVID-19 vaccination: Considerations for the collection and use of vaccination data: Interim Guidance [03-03-2021]
• COVID-19 vaccine checklist [03-01-2021]
• Health worker communication for COVID-19 vaccination flow diagram [03-01-2021]
• ChAdOx1-S [recombinant], COVID-19 vaccine [02-26-2021]
• COVID-19 vaccine introduction and deployment costing tool (CVIC tool): Version 2 pre-release [02-20-2021]
• AZD1222 vaccine against COVID-19 developed by Oxford University and Astra Zeneca: Background paper (draft) [02-10-2021]
• Background document on the mRNA-1273 vaccine (Moderna) against COVID-19 [02-03-2021]
• Data for action: achieving high uptake of COVID-19 vaccines: interim guidance [02-03-2021]
• Conducting community engagement for COVID-19 vaccines: Interim guidance [01-31-2021]
• Interim recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19 [01-25-2021]
• mRNA-1273 vaccine (Moderna) against COVID-19 Background document (draft) [01-19-2021]
• Aide-memoire: infection prevention and control (IPC) principles and procedures for COVID-19 vaccination activities [01-15-2021]
• Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing [01-08-2021]
• Evidence to recommendations for COVID-19 vaccines: evidence framework [12-10-2020]
• Guidance on developing a national deployment and vaccination Planning for COVID-19 vaccines [11-16-2020]
• Immunization as an essential health service: guiding principles for immunization activities during the COVID-19 pandemic and other times of severe disruption [11-01-2020]

CDC
• Interim public health recommendations for fully vaccinated people [04-02-2021]
• Updated Healthcare Infection Prevention and Control Recommendations in Response to COVID-19 Vaccination [03-10-2021]
• COVID-19 vaccination toolkits [03-09-2021]
• COVID-19 Vaccination [02-26-2021]

UK
• COVID-19 vaccination: guide for older adults [03-29-2021]
• COVID-19: vaccine surveillance strategy [03-29-2021]
• PHE monitoring of the effectiveness of COVID-19 vaccination [updated 03-26-2021]
• COVID-19 vaccination programme: collection [updated 03-23-2021]
• COVID-19 vaccination: women of childbearing age, currently pregnant or breastfeeding [03-01-2021]
• COVID-19 vaccination: information for healthcare practitioners [updated 02-26-2021]
• COVID-19: the green book, chapter 14a [02-12-2021]
• National protocol for COVID-19 Vaccine AstraZeneca (ChAdOx1-S [recombinant]) [01-10-2021]
• National protocol for COVID-19 mRNA vaccine BNT162b2 (Pfizer/BioNTech) [01-10-2021]

ECDC
• Rollout of COVID-19 vaccines in the EU/EEA: challenges and good practice [03-29-2021]
• Overview of the implementation of COVID-19 vaccination strategies and vaccine deployment plans in the EU/EEA, [03-29-2021]
• Stress test on logistical aspects of COVID-19 vaccination deployment plans: final report [02-03-2021]
• Integrated COVID-19 response in the vaccination era [02-01-2021]
• COVID-19 vaccination and prioritisation strategies in the EU/EEA [12-22-2020]
Section III: Guidelines for the Community

Community

PHAC
- Community-based measures to mitigate the spread of coronavirus disease (COVID-19) in Canada [modified 10-15-2020]

CDC
- Operational considerations for community isolation centers [03-18-2021]
- People who are at increased risk for severe illness [updated 03-15-2021]
- Pregnancy & breastfeeding: information about coronavirus disease 2019 [updated 02-26-2021]
- Communities of faith [02-19-2021]
- Community, Work, and School [updated 02-05-2021]
- Considerations for aquatic venues [updated 02-01-2021]
- Community organizations & gatherings [updated 01-21-2021]
- Considerations for election polling locations [updated 01-04-2021]
- Playing sports [updated 12-31-2020]
- Considerations for retirement communities & independent living facilities [12-31-2020]
- Parks and recreational facilities [updated 12-31-2020]
- Care for breastfeeding women [12-03-2020]
- Guidance for Pharmacies [11-13-2020]
- COVID-19 employer information for banks [10-29-2020]
- COVID-19 response health equity strategy: accelerating progress towards reducing COVID-19 disparities and achieving health equity [08-21-2020]

UK
- National lockdown: stay at home [updated 04-06-2021]
- COVID-19: how to work safely in domiciliary care in England [updated 04-06-2021]
- Coronavirus (COVID-19): providing unpaid care [03-31-2021]
- COVID-19: guidance for households with possible coronavirus infection [updated 03-12-2021]
- Coronavirus (COVID-19): looking after people who lack mental capacity [updated 01-12-2021]
- Government advice on home moving during the coronavirus (COVID-19) outbreak [updated 01-07-2021]
- Core COVID-19 information and guidance for general (non-healthcare) settings: version 4.8 [12-31-2020]

Australia
- Coronavirus (COVID-19) information about routine environmental cleaning and disinfection in the community [11-30-2020]

Other
- Faith-based, spiritual, and worship practices [03-29-2021]
Masks (Non-Medical)

Ontario Ministry of Health

- Guideline for the management of the healthy newborn born to a pregnant mother/individual who is confirmed or suspect case of COVID-19 [09-04-2020]
- Public Health guidance for community volunteers during the COVID-19 pandemic [07-20-2020]

Health Canada

- Face coverings and face masks [updated 03-23-2021]

World Health Organization (WHO)

- Non-medical masks and face coverings: about [modified 02-11-2021]
- Advice on the use of masks in the context of COVID-19 [12-01-2020]

Centers for Disease Control and Prevention (CDC)

- Use of masks to help slow the spread of COVID-19 [02-16-2021]
- Guidance for wearing masks [04-06-2021]

European Centre for Disease Prevention and Control (ECDC)

- Use of gloves in healthcare and non-healthcare settings in the context of the COVID-19 pandemic [07-02-2020]

United Kingdom (UK)

- The Disabled Persons Transport Advisory Committee (DPTAC) position on face coverings [03-22-2021]

Businesses/Workplaces

Ontario Ministry of Health

- Resources to prevent COVID-19 in the workplace [updated 04-06-2021]

Public Health Agency of Canada (PHAC)

- Risk mitigation tool for outdoor recreation spaces and activities operating during the COVID-19 pandemic [09-28-2020]
- Risk mitigation tool for workplaces/businesses operating during the COVID-19 pandemic [modified 09-28-2020]

WHO

- COVID-19: Occupational health and safety for health workers [updated 02-02-2021]

Canadian provinces and territories (other than Ontario)

- QC COVID-19: Interim recommendations for workers providing personal care and esthetic services (e.g., hairdressing, esthetic and makeup services, manicures, tattooing, etc.) [05-28-2020]
CDC
- Interim guidance for SARS-COV-2 testing in non-healthcare workplaces [03-17-2021]
- Guidance for specific industries and occupations [02-08-2021]
- Meat and poultry processing workers and employers [02-06-2021]
- Considerations for restaurants and bars [updated 12-16-2020]

UK
- Working safely during coronavirus (COVID-19) [updated 03-31-2021]
- COVID-19: guidance for food businesses [01-06-2021]

Other

**Schools / Childcare**

Ontario Ministry of Health
- COVID-19: reopening child care centres [updated 03-10-2021]
- COVID-19: reopening schools [updated 03-04-2021]

PHAC
- COVID-19 guidance for schools Kindergarten to Grade 12 [02-12-2021]
- Risk mitigation tool for child and youth settings operating during the COVID-19 pandemic [09-28-2020]

WHO
- Considerations for school-related public health measures in the context of COVID-19: Annex to Considerations in adjusting public health and social measures in the context of COVID-19 [09-14-2020]

CDC
- Schools and childcare programs [reviewed 04-05-2021]
- Interim guidance for SARS-CoV-2 testing and screening at institutions of higher education (IHEs) [03-17-2021]
- Considerations for institutes of higher education [12-31-2020]
- Cleaning, disinfection & hand hygiene [02-22-2021]

UK
- Actions for schools during the coronavirus outbreak [updated 04-06-2021]
- Actions for early years and childcare providers during the coronavirus (COVID-19) outbreak [updated 03-31-2021]
- Higher education: reopening buildings and campuses [03-10-2021]
- Providing school meals during coronavirus (COVID-19) outbreak [03-10-2021]
- Objectives for COVID-19 testing in school settings [08-10-2020]

Other
- Public health guidance for child care settings during the COVID-19 pandemic [02-12-2021]
Mental Health / Addictions

Ontario Ministry of Health

- Guidance for consumption and treatment services sites: version 2 [amended 04-16-2020]

PHAC

- Helping people who use substances during the COVID-19 pandemic [09-01-2020]

Provinces & Territories (excluding Ontario)

- AB [link to document]
- QC [link to document]
- BC [link to document]
- BC [link to document]

WHO

- Smoking and COVID-19 [06-30-2020]
- Addressing violence against children, women and older people during the COVID-19 pandemic: key actions [06-18-2020]
- COVID-19 and violence against women: what the health sector / system can do [04-07-2020]

CDC / SAMHSA

- Health promotion to enhance healthcare worker performance during COVID-19 [updated 05-21-2020]
- Interim guidance for syringe services programs [05-15-2020]
- Considerations for the care and treatment of mental and substance use disorders in the COVID-19 epidemic: March 20, 2020 [revised 05-07-2020]
- Considerations for crisis centers and clinicians in managing the treatment of alcohol or benzodiazepine withdrawal during the COVID-19 epidemic: March 19, 2020 [03-19-2020]
- Considerations for outpatient mental and substance use disorder treatment settings [no date]
- Virtual recovery resources [no date]
- Intimate partner violence and child abuse considerations during COVID-19 [no date]

UK

- COVID-19: guidance for commissioners and providers of services for people who use drugs or alcohol [updated 03-31-2021]
- COVID-19: guidance on supporting children and young people’s mental health and well-being [updated 03-16-2021]
- COVID-19: guidance for the public on mental health and wellbeing [updated 02-22-2021]
- Domestic abuse: get help during the coronavirus (COVID-19) outbreak [updated 02-12-2021]

Other
• Free online crisis training for essential workers during the COVID-19 pandemic [2020]
• Risk mitigation in the context of dual public health emergencies [03-00-20]
• COVID-19: guidance for individuals experiencing abuse York University (Ontario) [no date]

Travel, Transport & Borders

Ontario Ministry of Health
• Guidance for public transit agencies and passengers in response to COVID-19 [12-03-2020]

Canada
• COVID-19: travel, quarantine and borders [04-01-2021]
• Guidance material for air operators managing travellers during the check-in procedure for flights departing from an aerodrome in Canada [modified 04-01-2021]
• Pandemic COVID-19 all countries: avoid non-essential travel outside Canada [04-01-2021]

CDC
• Global COVID-19 pandemic notice [reviewed 04-05-2021]
• Travelers returning from cruise ship and river cruise voyages [02-02-2021]

ECDC
• Guidelines for COVID-19 testing and quarantine and testing of travellers [03-12-2021]
• Guidelines for COVID-19 testing and quarantine of air travellers [12-02-2020]
• COVID-19 aviation health safety protocol [06-30-2020]

UK
• COVID-19: general aviation [updated 03-29-2021]
• COVID-19: safer travel guidance for passengers [updated 03-29-2021]
• COVID-19: safer transport guidance for operators [updated 03-29-2021]
• COVID-19: safer air travel for passengers [updated 03-29-2021]
• COVID-19: taxis and PHVs [03-29-2021]
• COVID-19: safer aviation guidance for operators [updated 03-08-2021]
• COVID-19: shipping and sea ports guidance [updated 09-24-2020]

Other
• Emergency response plan and action checklist for use by air carriers in the event of a public health emergency [no date]
• Take-off: guidance for air travel through the COVID-19 public health crisis [11-05-2020]